Deciphering Risk of Recurrent Bone Stress Injury in Female Runners Using 1 **Serum Proteomics Analysis and Predictive Models** 2

- **Authors:** Genevieve E. Romanowicz¹, Kristin Popp^{2,3,4}, Ethan Dinh¹, Isabella R. Harker¹, Kelly Leguineche¹, Julie M. Hughes⁵, Kathryn E. Ackerman^{2,3}, Mary L. Bouxsein^{2,6}, Robert E. 3
- 4
- Guldberg¹ 5

Affiliations: 67

- ¹Knight Campus for Accelerating Scientific Impact, University of Oregon, Eugene, OR 8
- 9 ²Endocrine Division, Massachusetts General Hospital, Boston, MA
- ³Boston Children's Hospital, Boston, MA 10
- ⁴TRIA Orthopedics, HealthPartners Institute, Bloomington, MN 11
- ⁵Military Performance Division, United States Army Research Institute of Environmental 12
- Medicine, Natick, Massachusetts, USA 13
- ⁶Center for Advanced Orthopaedic Studies, Beth Israel Deaconess Medical Center, Boston, MA 14
- *Corresponding author. Email: guldberg@uoregon.edu 15

16 Abstract:

Up to 40% of elite athletes experience bone stress injuries (BSIs), with 20-30% facing reinjury. 17 Early identification of runners at high risk of subsequent BSI could improve prevention strategies. 18 However, the complex etiology and multifactorial risk factors of BSIs makes identifying predictive 19 20 risk factors challenging. In a study of 30 female recreational athletes with tibial BSIs, 10 21 experienced additional BSIs over a 1-year period, prompting investigation of systemic biomarkers of subsequent BSIs using aptamer-based proteomic technology. We hypothesized that early 22 proteomic signatures could discriminate runners who experienced subsequent BSIs. 1,500 proteins 23 related to metabolic, immune, and bone healing pathways were examined. Using supervised 24 machine learning and genetic programming methods, we analyzed serum protein signatures over 25 the 1-year monitoring period. Models were also created with clinical metrics, including standard-26 of-care blood analysis, bone density measures, and health histories. Protein signatures collected 27 28 within three weeks of BSI diagnosis achieved the greatest separation by sparse partial least squares 29 discriminant analysis (sPLS-DA), clustering single and recurrent BSI individuals with a mean accuracy of 96 \pm 0.02%. Genetic programming models independently verified the presence of 30 candidate biomarkers, including fumarylacetoacetase, osteopontin, and trypsin-2, which 31 significantly outperformed clinical metrics. Time-course differential expression analysis 32 highlighted 112 differentially expressed proteins in individuals with additional BSIs. Gene set 33 34 enrichment analysis mapped these proteins to pathways indicating increased fibrin clot formation and decreased immune signaling in recurrent BSI individuals. These findings provide new insights 35 into biomarkers and dysregulated protein pathways associated with recurrent BSI and may lead to 36 37 new preventative or therapeutic intervention strategies.

One Sentence Summary: Our study identified candidate serum biomarkers to predict subsequent bone stress injuries in female runners, offering new insights for clinical monitoring and interventions.

- 41
- 42

43 Main Text:

44 INTRODUCTION

Bone stress injuries (BSIs) are common in active individuals, affecting professional and 45 amateur athletes (1 in 20 individuals) (1, 2) and military personnel undergoing initial military 46 training (as high as 1 in 10 individuals) (1, 3, 4). For athletes, BSIs are one of the most burdensome 47 injuries, with 20-40% of athletes experiencing BSIs during training (5, 6). While BSIs can range 48 in severity, they may have an outsized financial and psychological impact due to high rates of 49 50 additional BSIs and extended absences from sport (7). Methods to improve BSI healing, enhance early detection, and inform preventative strategies would remove an obstacle to training and 51 improve athlete well-being. Yet the etiology and pathogenesis of BSIs are multifactorial and 52 complex, making identification of a single factor leading to subsequent BSIs (new BSI at the same 53 or different location) and ultimately the prevention of new BSIs challenging. 54

55 A history of a prior BSI is one of the strongest risk factors for a recurrent BSI (2, 6). Diagnosis of these injuries is accomplished through magnetic resonance imaging (MRI), x-ray 56 based imaging, or clinical symptoms. The standard of care for return to play is based off absence 57 of pain with progressive physical activity after an initial period of rest/unloading. For high-risk 58 BSIs, repeat MRI may also be ordered to ensure healing. However, current biomarkers (8), clinical 59 assessments [MRI, dual-energy x-ray absorptiometry (DXA), and computed tomography (CT)] (9) 60 lack reliable sensitivity and specificity in identifying individuals at risk of subsequent BSIs. Return 61 to sport is highly individualized based on the patient specific risk factors and pain levels with 62 63 loading (10). Together, variability in diagnostics, prognostics, risk factors, and treatment regimens has made the identification of individuals at risk of subsequent BSIs challenging. 64

Although most runners with BSIs are able to return to activity after rest, the frequency of subsequent BSIs ranges from 20-30% (11, 12). Recurrence of BSIs at the same or different locations, are ~3 times greater in women compared to men (5). Recovery from a BSI can range from 4 weeks to 6 months (9, 12, 13), causing extended removal from sport. While thus far elusive, identification of a reliable biomarker or biomarker panel, would dramatically improve clinical decision making for return to activity and post-injury management as well as prevention and treatment of BSIs.

72 In our previously reported study, female recreational runners who experienced a subsequent BSI were younger, more likely to have a history of prior skeletal fracture, and had later 73 onset of menses and lower serum parathyroid hormone (PTH) levels than female athletes who did 74 not experience a subsequent BSI (11). Notably, bone density and microarchitecture was largely 75 similar between athletes who did and did not suffer a recurrent BSI, though women who had a 76 reinjury had lower cortical bone tissue mineral density (TMD) and estimated stiffness at the distal 77 78 tibia (11). Altogether, there was no set of clinical or performance-related factors that distinguished between individuals who would sustain a subsequent BSI during the one year follow up and those 79 who would heal uneventfully. This informed our current study with the objective to identify protein 80 81 signatures in individuals who experience subsequent BSIs to address these clinical challenges.

The identification of biomarkers in bone healing is an emerging field, supported by the development of sophisticated machine learning (ML) models designed to navigate the complexities of high-dimensional datasets characterized by limited sample sizes, multi-omic integration, and biological noise (14). Genetic programming-based ML approaches have proven effective in extracting critical insights from such datasets. Additionally, high-throughput

proteomic technologies, such as the SOMAscan assay (15-17), enable simultaneous quantification 87 of over 1,500 proteins from human serum with exceptional precision, enhancing the detection of 88 biological signals. However, these advancements also amplify the challenge of "small n" datasets, 89 where the number of variables vastly exceeds the sample size, increasing the risk of overfitting 90 (18). Despite this, when strong signals exist, it is possible to identify highly informative feature 91 sets which are predictive in the clinical context. 92

Our study leverages established machine learning and genetic programming models to 93 interrogate both linear and non-linear relationships within high-resolution proteomic data. By 94 combining advanced proteomic profiling with ML, we provide critical insights into diagnostics, 95 early intervention, and personalized risk assessment in sports medicine. Furthermore, our dataset 96 represents the most comprehensive serum proteomic analysis for BSI studies to date, illuminating 97 dysregulated biological pathways in an underexplored population of female athletes. 98

99 RESULTS

Study Cohort 100

101 Utilizing samples serum from our previous study (11), we sought to characterize the proteomic signatures of individuals with and without additional BSI's over a one-year recovery 102 period. The original study enrolled female recreational athletes (n=30) (Fig. 1) from the local 103 community who were diagnosed with a tibial BSI with MRI Grading of 2-4/4 by Fredericson 104 Criteria (11). Patients were enrolled within 3 weeks of initial BSI MRI diagnosis. At enrollment, 105 areal bone mineral density (aBMD) of the hip and spine were assessed by DXA, while volumetric 106 107 bone mineral density (vBMD) and bone microarchitecture at the distal tibia were measured via high-resolution peripheral quantitative computed tomography (HR-pOCT). HR-pOCT scans were 108 also collected at each follow up visit, including 6, 12, 24, and 52 weeks after the initial enrollment. 109 Additionally, clinical metrics were collected, including laboratory blood values, pain assessments, 110 physical activity assessments, menstrual status, and health and fracture history (full list in Data 111 File S1, data previously reported (11)). Of the 30-runner cohort, 10 experienced additional BSIs 112 at times ranging from 6-52 weeks after initial diagnosis (11). The majority occurred between weeks 113 114 12 and 52 (9 out of 10 additional BSIs) (Table 1). One individual had a third BSI event in the 24to-52-week period. Only one additional BSI was in the same location as the first BSI. For all 115 individuals, serum was analyzed retrospectively for protein signatures of additional BSI (full list 116 117 in Data file S2).

- 118
 - Table 1. Summary of additional BSI events during the 52 weeks of monitoring. A total of 10 of 30 participants experienced a 2nd BSI, with one individual experiencing a 3rd BSI. 119
 - Only one BSI was at the same location as the original BSI. Data previously reported in 120
 - Popp, et al., 2019. 121

Time Window	2 nd BSI	3 rd BSI
Enrollment - 6 weeks	1	
6 - 12 weeks	0	
12-24 weeks	5	
24-52 weeks	4	1
	10 Additional	
Total:	BSIs	



122

Figure 1: Study design and patient attrition. (A) Female recreational athletes were 123 recruited to participate in an observational study following bone stress injury (BSI) diagnosis 124 with an MRI Fredericson grade 2-4/4. Patient attrition and visit completion are noted. Figure 125 adapted from Popp, et al. 2019. (B) All patients were enrolled within 3 weeks of diagnosis 126 of a tibial BSI and monitored for metrics such as bone morphometry changes, physical 127 activity, and pain. Serum was collected and originally analyzed for standard of care 128 laboratory values. This study re-analyzed the serum for 1,500 proteins across all individuals 129 and times. Of the 30 individuals, 20 went on to recover without additional injury. 10 130 individuals experienced a second BSI, with one individual experiencing a third BSI over the 131 follow up (Table 1). Created in https://BioRender.com 132 one year

133 134

Additional and single BSI groups can be identified based on early protein signatures at time of enrollment and before any additional BSI events.

The sparse partial least squares discriminant analysis sPLS-DA model was chosen to 137 identify key features from the enrollment visit (visit 1, < 3 weeks after initial BSI diagnosis), 138 separating additional BSI individuals from single BSI individuals. Models were first applied to the 139 clinical outcomes (11). Separation was not clear for the clinical data, with the top-ten features 140 identified as age at menses onset, cortical TMD (Ct. TMD), compressive stiffness (Comp. Stiff.), 141 age, failure load (F. Load), and prior number of fractures (Prior FX) (Fig. 2A&D), all of which 142 were previously reported (11) to be different between additional and single BSI groups. Serum 143 procollagen type I N-propeptide (P1NP) and serum osteocalcin were also included in the top-ten 144 features (Fig. 2D, Data File S3). These serum metrics were measured using standard-of-care 145 clinical laboratory assays in the previous study (11), and are different than the aptamer based serum 146 147 proteomic data. Due to the small sample size, feature importance estimation via bootstrapping was conducted on the sPLS-DA models. The bootstrapping method included repeated removal of one 148 participant and recording of the top model features. Stable features, identified as those appearing 149 in at least 80% of models following bootstrapping (Data File S4), were then evaluated for 150 predictive performance via Receiver Operating Characteristic (ROC) analysis. Due to the small 151 sample size and class imbalance in the data, leave one out cross validation (LOOCV) was applied. 152 For the clinical data, the features selected were medical history (age, age at menses onset, prior 153 history of fracture), tibia morphology via HR-pOCT (CtTMD, stiffness and strength), and serum 154 markers of bone metabolism (P1NP, tartrate-resistant acid phosphatase 5b (TRAP5b)). The area 155 under the curve (AUC) for mean ROC curve indicated an average accuracy of $79\% \pm 0.08$ across 156 various predictive models including Logistic Regression, Random Forest, and CatBoost (Fig. 2G). 157 The average sensitivity was 63.3% and average specificity was 76.7% (Fig. S1A). The positive 158 predictive value was 57.6% and negative predictive value was 80.7% (Fig. S1A). 159

Similar models were generated for the serum proteomic data. sPLS-DA was performed on 160 serum proteomic data from the enrollment visit. Ten proteins were identified which segregated the 161 single vs. additional BSI groups (Fig. 2B). Of these, fumarylacetoacetase (FAAA), trypsin-2, and 162 adiponectin were identified with the highest coefficients and greatest influence on the models to 163 discriminate between single and additional BSIs (Fig. 2E). Less influential, but still important 164 features included soluble vascular endothelial growth factor receptor 2 (VEGF sR2), tumor 165 necrosis factor (TNF) receptor superfamily member 1B (TNF sR-II), osteopontin (OPN), telomeric 166 repeat binding factor 1 (TERF1), Hsp70-binding protein 1 (HPBPI), Bcl2-associated agonist of 167 cell death (BAD), and Interferon-induced helicase C domain-containing protein 1 (IFIH1) (Data 168 File S3). Features present in at least 80% of models were FAAA, tyrpsin-2, adiponectin, OPN, 169 TNF sR-II, VEGF sR2 (Data File S4). These proteins were then evaluated with an ROC analysis 170 and LOOCV. The AUC for the mean ROC curve indicated an average accuracy of 96% \pm 0.02 171 across various predictive models including Logistic Regression, Random Forest, and CatBoost 172 (Fig. 2H). The average sensitivity was 80.0% and average specificity was 98.3% (Fig. S1B). The 173 positive predictive value was 96.0% and negative predictive value was 90.8% Fig. S1B). The 174 proteomic data models performed better (mean AUC \pm S.E.) than clinical data (p = 0.012, one-175 way ANOVA). 176

To determine if combining datasets would improve accuracy of the models, we then repeated the sPLS-DA models with both the clinical and the proteomic datasets. Combined datasets slightly increased separation between the two patient populations (Fig. 2C). Yet, of the

top-10 variables, only one clinical metric (age at onset of menses) was included (Fig. 2F, Data File

181 S3). Features present in at least 80% of models included FAAA, trypsin 2, age at menses onset,

adiponectin, TNF sR-II, and OPN (Data File S4). These six features were then evaluated with a

183 ROC analysis and LOOCV. The AUC for the mean ROC curve indicated an average accuracy of

184 $95\% \pm 0.02$ across various predictive models including Logistic Regression, Random Forest, and

185 CatBoost (Fig. 2I). The average sensitivity was 80.0% and average specificity was 93.3% (Fig.

186 S1C). The positive predictive value was 85.7% and the negative predictive value was 90.3% (Fig.

187 S1C). While the average accuracy was similar between the proteomic data model and the combined

data model, the combined models had a small reduction in sensitivity with increased specificity.

The combined models performed better (mean AUC \pm S.E.) than clinical data (p = 0.017, one-way

ANOVA), but not better than proteomic data (p = 0.97, one-way ANOVA).

191



Figure 2: Bone stress injury (BSI) reinjury classification can be identified from 192 proteomic data within 3 weeks of initial BSI. (A) Clinical data were used to separate 193 additional from single BSI individuals with a sparse partial least squares discriminant 194 analysis (sPLS-DA) model but yielded no clear separation. (B) Proteomic signatures were 195 then tested in a similar model, increasing separation. (C) Combining both clinical and 196 proteomic data marginally improves separation. (D) The top latent variables for the sPLS-197 DA model are shown for clinical data, (E) proteomic data, and (F) the combined clinical 198 and proteomic data. (G) The most frequent variables identified by feature importance 199 estimation via bootstrapping were input into the sPLS-DA models and tested in predictive 200 models, including Logistic Regression, Random Forest, and CatBoost, each with leave 201 one out cross validation (LOOCV). Receiver operating characteristic (ROC) curves are 202 shown with a mean accuracy of $79\% \pm 0.08$ for clinical data, (H) 96% ± 0.02 for proteomic 203 data, and (I) $95\% \pm 0.02$ for the combined data. Shaded regions (A-C) represent the 95% 204 confidence interval. AUC values are mean \pm S.E. 205

Genetic programming models further support identification of candidate biomarkers of subsequent BSIs.

Genetic programming has become a useful tool to generate predictive models in biological 208 datasets where both linear and non-linear relationships may occur simultaneously (19, 20). We 209 thus explored if linear and non-linear models would improve the predictive accuracy of both the 210 proteomic and clinical datasets using Evolved Analytics DataModeler software. Thousands of 211 models are generated across at least 30 successive generations, in which "fit" models are 212 selectively bred. Finally, models are rated based on accuracy and complexity, and those with 213 optimal complexity/accuracy tradeoffs are aggregated into a model ensemble. Complexity refers 214 to a measure of numerical operations required to fit the data into either the additional or single BSI 215 group. Lower complexity is desirable, with a complexity score > 80 considered too complex for 216 our dataset based on sample size. Therefore, we sought to evaluate the complexity and accuracy 217 218 of produced models for each of our datasets. Resultant model ensembles were used to predict a binary outcome measure: single vs. additional BSI. This approach allowed for an independent 219 statistical validation of candidate biomarkers by utilizing a completely independent machine 220 learning approach as compared to the linear models used in sPLS-DA. An additional advantage of 221 genetic programing is that candidate equations that are used to generate the model ensembles are 222 displayed as an output, showing the algorithmic relationship between features and enhancing 223 224 interpretability.

Datasets were compared for accuracy and error including 'Clinical Data, 'Proteomic Data', 225 226 or 'Combined Data' with the same datasets tested in the sPLS-DA models. Ten candidate models were selected from the thousands of models generated per category. Candidate models were 227 228 restricted to 4 variables, which is the recommended number of variables to allow for at least a 5:1 ratio of datapoints (individuals) to support selected variables (Fig. 3A-C). The first step in 229 evaluating genetic programming model ensembles (collections of models) is to inspect if model 230 ensembles exhibit a 'knee' shaped Pareto plot, which signifies a balance between minimizing error 231 232 and avoiding unnecessary complexity. Minimizing error with balance complexity is a desirable trait in all models but is especially important with small datasets. The 'knee' shape was notably 233 absent in models relying solely on clinical data (Fig. 3A) suggesting that accuracy could not be 234 achieved without undue complexity and therefore risk of overfitting. Additionally, accuracy in this 235 context signifies confidence in a binary classification (e.g., single or additional BSI), rather than 236 estimate of a continuous variable. 237

Genetic programming models for the clinical metrics had the poorest performance, with 238 resultant 10-model ensemble (Table S1) yielding relatively low accuracy ($R^2 = 78\%$) and high 239 error rates for single BSI predictions ($17 \pm 14\%$) and for additional BSI predictions ($29 \pm 13\%$) 240 across the selected 10 best performing models (Fig. 3D&E). Substantial variability between model 241 ensembles was also present in clinical metrics alone (Fig. 3D). For the clinical models, the top-5 242 most frequently occurring variables across the model ensemble included tibial length (40%), 243 absolute lymphocyte count (40%), age at menses onset (40%), serum levels of 25 (OH) vitamin D 244 (30%), and posteroanterior lumbar spine bone mineral content (PA-BMC) by DXA (30%). 245 Furthermore, no variable was present in more than 50% of the selected models (Fig. 3F). The 246 complexity scores ranged from 35-205, achieving 15.2-80% accuracy, respectively. A complexity 247 score of 205 is extremely high and suggestive of overfitting. This ultimately led to highly complex 248 models with considerable variability (Fig. 3E). Most of the resulting models were linear, with 249 subsets of models being non-linear for the variables PA-BMD and PA-BMC (Fig. S2) 250

These results are in contrast with the model ensemble using proteomic data, which 251 demonstrated higher accuracy ($R^2 = 91.6\%$), mean complexity score of 70.3, and much lower 252 average error rates for single BSI predictions $(3 \pm 8\%)$ and for additional BSI predictions $(8 \pm$ 253 254 14%) across the selected 10 best performing models (Fig. 3D&E, Table S2). The expected 'knee' shape is present (Fig. 3B) in the proteomic models, allowing for exploration of a variety of models 255 with balanced accuracy and complexity. For the proteomic models, the top-5 most frequently 256 occurring variables across the models included FAAA (100%), OPN (100%), soluble leptin 257 receptor (LEPR) (90%), Serpin B5 (60%), and trypsin-2 (40%) (Fig. 3F). From the variable 258 distribution analysis of 2,435 generated models, a frequency of 60-100% in the resultant model 259 ensemble underscores the predictiveness and consistency of FAAA, OPN, LEPR, and Serpin B5 260 261 compared to clinical data, which did not have a single variable represented in more than 50% of models. Resultant models were primarily linear with non-linear models for OPN and LEPR (Fig. 262 S3) 263

Combining both clinical and proteomic data yielded the highest accuracy ($R^2 = 97\%$) and 264 lowest error rates for single BSI predictions $(3 \pm 8\%)$ and for additional BSI predictions $(5 \pm 9\%)$, 265 with a modest mean complexity score (63.2) across the selected 11 best performing models (Fig. 266 3D&E, Table S3). Again, the 'knee' shape is present in the model ensembles (Fig. 3C). When 267 clinical and proteomic data were combined, history of anorexia replaced LEPR as the third most 268 common frequent variable (67% of models) in the combined ensembles, yet history of anorexia 269 had not previously been identified in the clinical data models (Fig. 3F). Of note, only two 270 individuals had a history of anorexia nervosa. For the combined models, the top-5 most frequently 271 272 occurring variables across the selected models included FAAA (100%), OPN (100%), history of anorexia nervosa (72.7%), trypsin-2 (54.5%), red blood cell distribution width (RDW) (27.3%) 273 274 (Fig. 3F). Resultant models were primarily linear with non-linear models for FAAA and OPN (Fig. 275 S4)





Figure 3: Genetic programming models were evaluated for accuracy and complexity using clinical, proteomic, and combined datasets. Models were generated using genetic programming to create candidate models and evaluate complexity and accuracy. The top ten models are highlighted in red and blue circles. (A) Clinical data produced minimal models that were both accurate and complex, noted by the absences of the 'knee' configuration in the plot. (B) Proteomic data produced the characteristic 'knee' shape, allowing for exploration of features that generate highly accurate and minimally complex models. (E) Model accuracy was compared as well as (F) model complexity, with combined datasets performing best. (D) Variable presence in the model ensembles were compared between clinical, proteomic, and combined datasets. Clinical data lacked variables present in >50% of the generate models. In contrast, proteomic data produced 4 variables present in > 50% of models with FAAA appearing in 100% of models. Combined datasets performed similarly with the inclusion of a history of anorexia as the top feature from the clinical dataset.

Candidate biomarkers have a temporal expression pattern in additional vs. single BSI individuals.

293 The top protein features from the sPLS-DA and genetic programming models were analyzed over the one-year follow-up including baseline, 6, 12, 24, and 52 weeks. Exploring 294 candidate biomarker proteins across sPLS-DA models and genetic programming, we investigated 295 296 the temporal patterns of FAAA, trypsin-2, and osteopontin. FAAA levels were higher in individuals who experienced additional BSIs compared to those with a single BSI at enrollment, 297 week 6, and week 24 (enrollment, p = 0.004; week 6, p = 0.03; week 24, p = 0.05) (Fig. 4A). By 298 contrast, Trypsin-2 levels were consistently lower in individuals with additional BSIs compared to 299 those with a single BSI at all examined timepoints (enrollment, p = 0.002; week 6, p = 0.02; week 300 12, p = 0.003; week 24, p = 0.01; week 52, p = 0.003) (Fig. 4B). OPN levels were higher in 301 individuals with additional BSIs compared to those with a single BSI at enrollment and week 24 302 (enrollment, p = 0.01; week 24, p = 0.005) (Fig. 4B). Given that the occurrence of additional BSIs 303 304 varied in timing among individuals, we were unable to identify the FAAA, trypsin-2, or OPN levels that corresponded to the timing of the second or third BSI onset. 305

We further explored the time dependent differences in key features from the sPLS-DA 306 307 models, specifically characterizing VEGF sR2, TNF sR-II, and adiponectin (Fig. D-F). VEGF sR2 levels were higher in individuals who experienced additional BSIs compared to those with a single 308 BSI at enrollment, week 6, and week 24 (enrollment, p = 0.01; week 6, p = 0.04; week 24, p =309 0.05) (Fig. 4D). By contrast, TNF sRII levels were consistently lower in individuals with additional 310 311 BSIs compared to those with a single BSI at all examined timepoints (enrollment, p = 0.02; week 6, p = 0.01; week 12, p = 0.003; week 24, p = 0.01; week 52, p = 0.0002) (Fig. 4E). Adiponectin 312 levels were lower in individuals with additional BSIs compared to those with a single BSI at 313 enrollment and week 24 (enrollment, p = 0.004; week 24, p = 0.05) (Fig. 4F). Again, the protein 314 levels were most different between groups at enrollment and at week 24, immediately following 3 315 additional BSIs events (Table 1). Yet, proteomic expression of FAAA and Trypsin-2 showed 316 317 sustained temporal patterns in proteomic levels between single and additional BSI groups (Fig. 4A&B). Notably, week 24 was different for FAAA, trypsin-2 and OPN, which followed 5 of the 318 additional BSI events and preceded 5 more BSIs (Table 1), suggesting that these proteins may be 319 320 elevated following or prior to subsequent BSI.

321



Figure 4: Serum proteins represented in predictive models displayed distinct 322 expression patterns over time between additional and single bone stress injury (BSI) 323 groups. (A-C) Proteins identified in both sparse partial least squares discriminant analysis 324 325 (sPLS-DA) and genetic programming models, such as fumarylacetoacetase (FAAA), trypsin-2, and osteopontin (OPN), exhibited temporal expression differences. (D-F) 326 Proteins identified only in the sPLS-DA model, including vascular endothelial growth 327 factor receptor 2 (VEGF sR2), tumor necrosis factor receptor superfamily member 1B 328 (TNF sR-II), and adiponectin, also showed significant temporal variation. Data are 329 presented as mean \pm SEM (n = 10 for additional BSI, n = 20 for single BSI, analyzed using 330 linear mixed-effects model (*p < 0.05, **p < 0.001). 331 332

Additional BSI was associated with early dysregulation in proteins involved in blood clotting and immune function

While proteomic analysis was useful for the biomarker identification and risk 335 classification, biomarkers alone do not give insights into biological pathways involved in 336 additional BSI risk. Therefore, functional pathways altered between additional and single BSI 337 groups were assessed through a gene set enrichment analysis (21). Proteins were first analyzed for 338 differential expression between groups while blocking for time using the ExpressAnalyst package 339 (22) based on the limma package (23) in R (R 4.4.1). This analysis revealed 112 significantly 340 different proteins expressed between additional and single BSI individuals $[\log_2 FC > 0.5]$, 341 Benjamini-Hochberg false discovery rate (FDR) adjusted p-value < 0.05] (Data File S5). Notably, 342 76 of these genes were found to be upregulated, while 36 were downregulated, indicating 343 substantial biological divergence that corresponds to subsequent BSIs (Fig. 5A). Of these proteins, 344 345 several key proteins identified in sPLS-DA and genetic programming models were also significantly differentially expressed proteins, including FAAA, trypsin-2, OPN, TNFs RII, VEGF 346 sR2, LEPR, and adiponectin (Fig. 5A). 347

To enable Gene Set Enrichment Analysis (GSEA) with proteins, the initial panel of 1,500 348 proteins were mapped to 1,207 corresponding unique genes via EntrezID to enable the analysis 349 through established gene network databases. Dysregulated pathways were identified in individuals 350 with an additional BSI as compared to a single BSI. Downregulated pathways in the additional v. 351 single BSI groups included immune system function, adaptive and innate immunity, interleukin-352 353 10 (IL-10) signaling, neutrophil degranulation, and signaling by interleukins (Fig. 5C). Significantly upregulated pathways in the additional v. single BSI included formation of fibrin 354 355 clot, intrinsic pathway of fibrin clot formation, and hemostasis (Fig. 5C). A full list can be found in the supplement (Data File S6). Of the significant pathways, six are primarily associated with 356 the immune system, while the remaining three are linked to blood clotting processes. Formation 357 of fibrin clot (clotting cascade) (R-HSA-140877) included protein C (PROC), a2-macroglobulin 358 359 (A2M), kallikrein B1 (KLKB1), thrombin (F2), and coagulation factor VII (F7) (Fig. 5B). Immune system (R-HAS-168256) included 24 immune system related proteins, notably trypsin-2 and TNF 360 sRII, which were present in the sPLS-DA models (Fig. 5B). 361

Because blood clotting pathways were significantly upregulated in additional BSI 362 individuals, we explored if type of contraceptive (combined oral, progestin-releasing IUD, 363 previously history of combined oral, or never used) contained any overlap with the protein profile 364 identified in additional BSI individuals. Hormonal contraceptives may influence blood clotting 365 pathways (24) as well as bone density and metabolism (25) and may be a confounding factor in 366 this study. However, our sPLS-DA analysis of protein signatures relating to type of contraceptive 367 did not contain overlapping proteins with the dysregulated proteins in the additional BSI 368 individuals (Fig. S4 A&C). We also explored if MRI grade was associated with the dysregulated 369 proteins in this study but found no overlap in MRI grade proteins and BSI risk proteins (Fig. S4 370 371 B&D).





381

Figure 5: Individuals with additional bone stress injury (BSI) show increased blood 373 clotting and decreased immune system proteins over time. (A) Volcano plot of 374 differentially expressed serum proteins up- or downregulated in additional BSI v. single 375 BSI individuals. (B) Heatmap of proteins from pathways including "formation of fibrin 376 clot" and "immune system" that were identified in (C) a gene set enrichment analysis of 377 differentially expressed proteins in additional BSI v. single BSI individuals. All data are 378 aggregated per individual over 52 weeks and analyzed, blocking for time, for both the 379 differential expression and gene set enrichment analysis (GSEA) analysis. 380

382 **DISCUSSION**

Pathogenesis of BSIs is both complex and remains poorly understood. Biological and 383 biomechanical factors contribute to subsequent BSIs, but clear clinical risk indicators are lacking. 384 This study aimed to identify protein signatures in individuals who experience subsequent BSIs to 385 address these clinical challenges. We conducted an in-depth proteomic analysis of female athletes 386 with and without recurrent BSI. Our findings revealed that subsequent BSI risk can be predicted 387 by early serum proteomic profiles. Using multivariate modeling, a sparse partial least squares 388 discriminant analysis (sPLS-DA) model identified six candidate biomarkers (FAAA, trypsin-2, 389 OPN, TNF sR-II, and VEGF sR2) with an accuracy of 91-96% in predicting recurrent BSI risk 390 category from enrollment proteins alone. Analysis of protein changes over time revealed 112 391 significantly different proteins, mapped to biological pathways associated with decreased immune 392 system function and increased blood clotting pathways. 393

Genetic programming further validated the candidate biomarkers, identifying FAAA as a 394 key predictor of subsequent BSIs. Notably, clinical metrics alone were insufficient to distinguish 395 between single and recurrent BSI groups. While combining clinical metrics with proteomic data 396 slightly enhanced genetic programming models, combined data did not outperform proteomic data 397 in sPLS-DA models, demonstrating the superior predictive power of proteomic information. This 398 integration of high-resolution proteomic data enabled the application of standard machine learning 399 methods on a relatively small dataset, surfacing a highly informative feature set far surpassing the 400 predictive value of standard clinical data. Our study not only provides the most comprehensive 401 402 proteomic dataset for BSIs in the underexplored population of female athletes but also identifies candidate biomarkers for recurrent BSIs, offering valuable insights for targeted therapeutic 403 404 interventions and improved clinical prediction strategies.

Multivariate linear regression models through sPLS-DA identified FAAA as the marker 405 (at enrollment, < 3 weeks of initial BSI) that most positively correlated with additional BSI and 406 407 Trypsin-2 as the marker (at all time points) most negatively correlated. These proteins have not been previously identified as biomarkers for BSI risk, and their role in bone health is not well 408 understood. FAAA has been implicated as a serum biomarker for idiosyncratic drug-induced liver 409 410 injury when increased (26, 27) and as a urine biomarker for acute hypercoagulable states in preclinical models when decreased (28, 29). In drug-induced liver inflammation, FAAA positively 411 correlates with alanine aminotransferase (ALT) (26). While ALT was not assessed in our clinical 412 metrics, ALT was measured via our Somamer panel and was found to positively correlate with 413 FAAA levels (Fig. S5, Adj. $R^2 = 0.19$, p < 0.0001), yet no overt liver diseases were reported in 414 patient medical histories. Alcohol consumption was also not evaluated in this study. Participants 415 were taking a variety of medications, precluding any clear correlations with potential drug-induced 416 liver injury. Another consideration is the use of athletic or herbal supplements, which can be 417 associated with liver injury (30) but are difficult to track due to poor reporting and labeling. 418 Although we did not adequately assess supplement intake in this study cohort, other studies have 419 shown that runners with a history of BSI report more frequent supplement intake (31) and athletes 420 generally take more types of supplements than non-athletes, with elite athletes having the highest 421 rate of supplement use (32, 33). In the additional BSI group, the proteins FAAA, aldehyde 422 423 dehydrogenase 1 family member B1 (ALDH1B1), and cytochrome P450 family 3 subfamily A member 4 (CYP3A4) were all upregulated together and relate to the functional pathway of 424 "metabolism" (R-HSA-1430728). Both ALDH1B1 and CYP3A4 are liver enzymes that regulate 425 drug metabolism (34) and alcohol metabolism(35). Therefore, elevated liver metabolism enzymes 426

such as FAAA, ALDH1B1, and CYP3A4 suggest a potential challenge to the liver that may be
due to supplement use or alcohol intake. Liver health status should be further considered for those
at risk of recurrent BSI.

Trypsin-2, also known as PRSS2 or tumor-associated trypsin, has been implicated as a 430 biomarker in pancreatitis (36), ulcerative colitis (37), and diabetes (38), as well as the progression 431 of tumor growth by immunosuppression via interaction with myeloid cells (39). Only recently has 432 trypsin-2 been described in human bone marrow, specifically in the hematopoietic stem cell niche 433 and highly expressed in early, undifferentiated hematopoietic progenitor cells and mobilized 434 $CD34^+$ hematopoietic cells (40). However, understanding of the role of trypsin-2 in the bone 435 marrow is limited to the maintenance of the stem cell niche by complex diffusion interaction in 436 the local microenvironments (40), not serum accumulation and potential endocrine signaling 437 within bone marrow. Here we observed that trypsin-2 levels were the strongest positive correlative 438 439 variable in the sPLS-DA models and the fourth most frequent variable in genetic program models of combined proteomic and clinical data. Trypsin-2 was increased in the single BSI group 440 compared to the additional BSI group at all time points. Only trypsin-2 and TNF sRII were found 441 to be different at all timepoints in the additional BSI group. The diminished trypsin-2 in the 442 additional BSI group corresponds with a reduction in immune pathways, including neutrophil 443 degranulation and innate immune system function, both of which contain trypsin-2 within the 444 pathway categories. These data highlight that elevated serum trypsin-2 levels are positively 445 correlated with successful BSI recovery at early time points and throughout the time course of 446 healing. Diminished trypsin-2 was accompanied by immunosuppressive pathways, suggesting a 447 role for diminished innate immune signaling in those with additional BSIs. A limitation of the 448 interpretation of the absolute levels of trypsin-2 is that this study did not include an uninjured 449 control group, so we cannot determine how the level of trypsin-2 relates to other health conditions 450 in which it has been identified as a biomarker. 451

Osteopontin (OPN) was identified as the second most frequent variable in genetic 452 programming models for both the proteomic and combined models, occurring in 100% of the 453 models selected in the model ensemble. Yet, OPN was only a modest negative predictor of 454 additional BSI in the sPLS-DA models. OPN also did not appear in any of the differentially 455 expressed pathways but was increased in additional BSI individuals at enrollment and at 24 weeks 456 post injury. OPN was found to be elevated in severe liver dysfunction (41), as well as with severe 457 inflammatory injury and sepsis (42). Elevated levels of OPN are associated with unfavorable 458 prognoses, including mortality, in critically ill patients with SARS-CoV-2 (COVID19) (43). 459 Broadly, OPN is known to have an inflammatory role, and is associated with other pro-460 inflammatory cytokines, such as C-reactive protein (CRP) and interleukin-6 (IL-6), all of which 461 have been shown to increase following bone trauma (44). We also observed in our time course 462 analysis that OPN peaked in the additional BSI group both at the enrollment visit (within 3 weeks 463 of BSI diagnosis) and again at week 24. This OPN 24-week peak was after an additional BSI in 5 464 individuals and preceded an additional BSI in 5 others. The elevated levels of OPN and other 465 proteins, at both baseline and week 24 (in and around the additional BSI events), strengthens the 466 evidence that such proteins correspond to injury-related biomarkers. Overall, elevated OPN in the 467 additional BSI group suggests a chronic inflammatory condition. 468

While immunosuppressive markers are known to correlate to increased fracture risk, this
 is primarily understood for comorbidities such as organ transplantation and steroid use (45).
 Similar mechanisms in otherwise healthy populations have not been well studied. However,

intense exercise and overtraining can cause a diminished immune response (46) and intense 472 exercise produces a robust inflammatory response (47), highlighting a knowledge gap in the role 473 of the immune system in bone quality in athletes. Our pathway analysis for proteins up- or down-474 regulated with additional BSI risk indicates an impaired or suppressed immune response, which 475 may delay or complicate the recovery process following an injury. In multiple patient studies 476 involving traumatic bone injuries, sustained immune suppression has corresponded to impaired 477 bone healing (48). Of note, IP-10 (also known as C-X-C motif chemokine 10 (CXCL10)), was 478 decreased in the additional BSI group in our time-independent analysis. We have previously shown 479 that serum levels of IP-10 correlated with poor bone healing outcomes in preclinical models of 480 severe muscle and bone trauma with cellular evidence of prolonged immunosuppression (14). 481

We observed biologically upregulated pathways related to fibrin clot formation, the 482 intrinsic clotting cascade, and hemostasis. Intense exercise is known to induce both coagulation 483 484 and fibrinolysis, a process typically balanced under normal conditions (49). In our study, we noted an increase in thrombin (F2), a key regulator of hemostasis (50). This increase was not associated 485 with the severity of fractures, as thrombin was not associated with the sPLS-DA for MRI grade 486 (Fig. S4 B&D). While oral contraceptives are thought to create a clinically prothrombotic state, 487 affecting both coagulation and fibrinolysis, we found no association between contraceptive use 488 and blood clotting proteins (Fig. S4 A&C). Elevated proteins within the fibrin clot formation 489 490 pathways included intrinsic clotting factors, such as KLKB1 and PROC, and extrinsic clotting factors, including coagulation F7, F2, and A2M. The pro-coagulation proteins were elevated 491 alongside inhibitory proteins. Therefore, without functional coagulation assessment, our 492 493 conclusions are limited to the elevation of proteins attributed to blood clot formation and hemostasis pathways. These findings are consistent with other studies of athletes undergoing 494 intense exercise training (47, 49, 51, 52). In the present study, we did not observe differences in 495 training level between the single and additional BSI groups (11). Therefore, elevated pro-496 coagulatory proteins suggest that the additional BSI group might be more affected by exercise-497 498 related coagulation changes, thereby increasing their risk of subsequent BSIs.

Surprisingly, none of the clinical bone morphometric data were determined to be frequent 499 variables in our combined clinical and proteomic models corresponding to additional BSI risk. 500 Variables appear more frequently in the model ensembles if the features hold higher influence on 501 502 predictive models and provide generalizability to the larger dataset. In the original study, we observed a decrease in cortical TMD and a decrease in finite element model analysis (FEA) 503 stiffness from the distal tibia in the additional vs. single BSI groups (11). Tibial cortical TMD 504 appeared in the sPLS-DA clinical models as well as tibial cortical vBMD, both of which were 505 acquired using HR-pQCT. Whereas in genetic programming models, the DXA-based lumbar spine 506 BMC appeared in the clinical model ensemble. Interestingly, in the combined model ensemble, 507 DXA-based BMC was replaced by RDW, which has previously been negatively correlated to 508 DXA-based BMD and increased risk of fracture (53, 54). Neither the genetic programming nor 509 sPLS-DA clinical models were highly predictive for clinical data alone. Tibial length was included 510 as the most frequent variable in the genetic program models of clinical metrics alone, but frequency 511 in the models was 40% and comparable to frequency of other top variables, including absolute 512 lymphocyte count (40%), vitamin D (30%), and age at menses onset (30%). Together, this implies 513 that the clinical data variable are present in a relatively flat data plane are likely overfitted in our 514 relatively small dataset. We would expect that if the clinical models were tested on a new dataset, 515 they may not perform well in stark contrast to the proteomic datasets. 516

When proteomic and clinical data were combined, history of anorexia nervosa emerged as 517 the third most frequent variable, present in 72.7% of the models, replacing LEPR. This finding 518 suggests that both a history of anorexia nervosa and LEPR protein levels may be interchangeable 519 in our models in relation to BSI outcomes. Low leptin levels are consistently noted in those with 520 low weight anorexia nervosa (55–57). However, given that only five individuals in our study had 521 a known history of anorexia, a follow up study would be needed to specifically evaluate the role 522 of anorexia in our recurrent BSI models in a larger sample size. Problematic or prolonged low 523 energy availability (LEA) from an eating disorder or disordered eating can lead to Relative Energy 524 Deficiency in Sport (REDs), a syndrome in which bone quality and health are often impaired (58). 525 LEA is major risk factor for BSI occurrence (59), so our finding of a history of anorexia being a 526 positive predictor of subsequent BSI is not surprising. While no participants had a known current 527 eating disorder throughout the study, it is plausible that they still had subclinical disordered eating 528 or that there are lasting effects of a past anorexia diagnosis on metabolic function or lifestyle. 529 Therefore, in our study, a history of anorexia may be supplemented in the models to simplify and 530 improve the accuracy of the genetic programming models by replacing several individual proteins. 531

Our study achieved ~97% accuracy in predicting additional BSIs using sPLS-DA and 532 genetic programming models with primarily proteomic data and effectively identified candidate 533 biomarkers in relatively small biological datasets. This highlights how high-resolution proteomic 534 data can enhance the predictive power of models through the synergistic effects of standard 535 machine learning models with the appropriate dataset. However, evaluating model performance 536 solely on error rates may not fully assess effectiveness. Genetic programming suggests that 537 increased complexity can lead to less generalizable models, making it crucial to examine model 538 distributions within the ensemble. Ideally, ensembles should exhibit a 'knee' shape in their context 539 plot, balancing error minimization and complexity. In our study, this 'knee' configuration was 540 absent in models relying solely on clinical metrics, indicating inefficiencies and potential 541 overfitting. Conversely, proteomic models showed lower error rates and retained the 'knee' shape. 542 543 This demonstrates that integrating detailed biomolecular profiles enhances the robustness and accuracy of predictive models in clinical applications. 544

Our study has several limitations. While our results identified significant correlations 545 between specific proteins and recurrent BSIs, establishing causal relationships would require 546 547 further investigation. Multivariate models based on high dimensional, low sample size datasets are common in clinical research but face challenges like possible overfitting and increased complexity, 548 complicating validation and interpretation. We sought to overcome these limitations by using both 549 sPLS-DA and genetic programming models to explore both linear and non-linear relationships in 550 the data as well as independent models with different assumptions. While most features presented 551 as linear relationships in our datasets, there were subsets of proteomic data that were identified as 552 non-linear relationships in genetic programming model ensembles, validating that both linear and 553 non-linear relationships should be explored. 554

555 Our results were also limited to the demographics of the study group, which includes 556 relatively healthy, young female athletes with diagnosed BSI as well as a skewed distribution of 557 individuals. Although our study demonstrated clear clustering between the study groups, we lack 558 a test population to fully validate the identified candidate biomarkers for subsequent BSIs. 559 Additionally, we lacked an injury-free control group, which would have aided in understanding 560 the protein levels regarding health or disease. Nevertheless, our study identified 10 significant 561 candidate biomarkers that appeared in 80% of the sPLS-DA models, including FAAA,

Osteopontin, and Trypsin-2, with a predictive accuracy of $95 \pm 0.02\%$ validated through leaveone-out cross-validation. Time-course differential expression analysis highlighted 112 differentially expressed proteins linked to pathways of increased fibrin clot formation and decreased immune signaling in individuals with additional BSIs. Our data highlight differences based on subsequent BSI risk in a relatively homogeneous study population (young, female athletes), adding to the strength of these findings as they relate to additional BSI risk in our study population.

The clinical implications of our study include the identification of (1) candidate biomarkers 569 of subsequent BSIs in young, female athletes, (2) pathway signatures of immunosuppression and 570 increased blood clotting with subsequent BSIs, and (3) an innovative approach to identifying and 571 validating candidate biomarkers in relatively small clinical study populations. Further studies are 572 required to prospectively validate FAAA, OPN, and Trypsin-2 as biomarkers of subsequent BSIs, 573 574 as well as their relationship in a broader study population. Additionally, the relationship between functional immunosuppression and increased blood clotting should be further explored in athletes 575 with BSI. 576

In conclusion, this study presents a robust statistical workflow, enhanced by machine 577 learning, to analyze high-resolution proteomic data, paving the way for advancements in reinjury 578 risk assessment. Our study underscores a critical gap in sports medicine: clinical metrics alone are 579 insufficient to predict risk of recurrent BSIs, leading to potential discrepancies in determining 580 appropriate rehabilitation and return to activity protocols. Our data reveal that specific protein 581 582 signatures within three weeks of an initial BSI uniquely identify individuals at risk for subsequent BSI within 52 weeks. While biomarker discovery in small datasets is challenging, advances in 583 584 proteomic technologies and machine learning can help isolate critical proteins that differentiate those with single BSIs from those at higher risk of additional BSI. Through multi-modeling, 585 subsampling, and cross-validation, we consistently identified candidate biomarkers, reinforcing 586 their potential as early indicators of additional BSIs. The network analysis of these proteins offers 587 588 deeper insights into the biological mechanisms underlying subsequent BSI risk. These findings not only enhance our understanding of the pathophysiology of BSIs, but also suggest new avenues for 589 preventive strategies and personalized medicine in sports, with the potential to reduce the 590 591 incidence and impact of recurrent injuries. 592

593 MATERIALS AND METHODS

594 Study Design

The design of the clinical study was previously published (11). In brief, local community 595 recreational female runners who had been diagnosed with a BSI of MRI Fredericson grade 2-4/4 596 (9) were enrolled in the study and monitored over 52 weeks. Inclusion criteria included a minimum 597 of 4 hours/week of self-reported weightbearing exercise during the 6 months prior to injury. 598 Exclusion criteria included known medical conditions that would affect bone health (e.g., current 599 eating disorder, hyperparathyroidism, celiac disease). Exclusion also included medications known 600 to affect bone health (e.g., oral steroids, bisphosphonates, lithium). Enrollment attrition is 601 summarized in Fig. 1, with loss due to disinterest (2 participants), diagnosis > 3 weeks (2 602 participants), lack of physical activity (1 participants), and dropped participation (2 participants). 603 Four participants missed more than 1 visit (Fig. 1). Timepoints include enrollment (within 3 weeks 604 of BSI diagnosis), 6, 12, 24, and 52 weeks post-enrollment. Participants were monitored for 605 activity levels, bone density (DXA and HR-pQCT), clinical standard-of-care labs, and 606 development of additional BSIs. Over the course of the study, 10 participants developed a 2nd BSI, 607 one of whom developed a 3rd BSI (Table 1). The remaining 20 participants went on to heal and 608 return to activity uneventfully. Following this study, we re-analyzed serum from all 30 final 609 participants to retrospectively determine the proteomic signatures between those with a single vs. 610 additional BSI. Proteomic data are all newly generated data and all analyses are new, including 611 those with clinical data that have been previously published (11). 612

To overcome the small clinical sample size, multiple machine learning algorithms were 613 applied to determine robust proteomic signatures in those with an additional BSI compared to those 614 with a single BSI. These models included sPLS-DA combined with non-parametric machine 615 learning models: CatBoost (60), logistic regression (61), and random forest (62). LOOCV was 616 applied to sPLS-DA models to provide robust sub-sampling of the data during model building to 617 618 ensure no single individual was skewing the protein signatures. Finally, protein signatures were analyzed for key biological pathway signatures to glean insights into the systemic dysregulation 619 in those with additional BSIs. This study was approved by the institutional review boards of 620 621 participating institutions and informed consent was obtained prior to participation.

622 Dataset

The clinical study was previously published (11) and was restricted to the clinical and HR-623 pQCT data. New analyses of the serum proteins were completed and the subsequent bioinformatic 624 approach combined the prior and new data. The current dataset consisted of 30 individuals, 10 of 625 whom experienced a new BSI event during the 1 year of follow-up. For each participant, the serum 626 was analyzed with a custom panel of 1,500 proteins by the SOMAscan (SomaLogic, Boulder, CO, 627 628 USA) (Data File S2). Detailed methods for the SOMAscan assay have been previously published (63). In brief, aptamer-based protein capture is utilized to multiplex the analysis and quantify 629 protein levels in a microarray-based technology. 630

Initially, raw clinical data from the original study (*11*) were meticulously reviewed to discern which metrics were relevant. We excluded some variables, such as types and frequency of exercise and height, which were deemed extraneous and/or noisy for modeling BSI risk. Additionally, to maintain consistency across the data, categorical variables, such as contraceptive use, were standardized as categorical variables. A comprehensive workflow was then created to preprocess the data and create data structures amenable to machine learning approaches.

637 Proteomic Panel Selection & SomaLogic Assay

Previous literature was initially examined to identify key proteins of interest. This led to 638 the curation of a list containing 1,500 target proteins, each selected for its association with relevant 639 physiologic categories from pre-fabricated panels provided by SomaLogic, such as 640 'Cardiovascular Disease', 'Inflammation and Immune Response', 'Metabolic Disease', and 641 'Oncology', as well as identified proteins of interest from literature (64-66) (full list in Data File 642 S2). To efficiently align these proteins with the naming convention used by SomaLogic, a 643 specialized Python program was developed. This program automatically translates gene names, as 644 cited in prior research, into UniProt IDs. Consequently, a custom panel featuring these 1,500 645 relevant proteins was created, providing a focused and comprehensive proteomic assay for our 646 study. 647

Following custom panel creation, serum samples from clotted blood were supplied to 648 SomaLogic for aptamer-based analysis. Samples were obtained from 30 individuals from the prior 649 BSI study (11). SomaLogic assay has been described previously. In brief, samples are analyzed 650 with custom slow off-rate aptamers designed for up to 7,000 human proteins. Concurrent analysis 651 of the custom 1,500 protein panel is done from 55 uL of serum and samples are normalized with 652 SomaLogic's custom and robust internal and plate-to-plate normalization methods (67). Standard 653 mathematical normalization techniques (\log_2 and mean centering) were applied before further 654 processing. A subset of samples were flagged (6/145 samples) because the samples failed to 655 hybridize in the initial step and were re-run successfully. Flagged samples can occur with bubble 656 657 formation or other technical difficulties during assay processing.

658 Data Preprocessing

Optimal data preprocessing was identified by comparing the methods: standardization, 659 variance stabilization normalization (VSN), quantile, linear-regression, and mean-centered 660 approaches, each of which are widely accepted preprocessing methods. Resulting box-plot 661 distributions were compared for equitable distribution of the data and standardization emerged as 662 the most effective normalization technique. Transformation was similarly scrutinized, with log₂, 663 \log_{10} , and box-cox evaluated. The \log_2 transformation was selected because it stabilized the 664 variance of high intensities but increased the variance at low intensities, allowing for more uniform 665 evaluations (68). Standardization and \log_2 transformations were applied to all datasets. 666

667 Machine Learning Sparse Partial Least Square Discrimination Analysis (sPL-DA)

668 Clinical and proteomic data were compiled for analysis using custom Python and R scripts 669 designed for feature reduction and multivariate modeling. Sparse Partial Least Square 670 Discriminant Analysis (sPLS-DA) was conducted in R (R 4.4.1) using the MetaboAnalystR 4.0 671 (*69*) package. Prior to analysis, the data were preprocessed as described above.

The sPLS-DA method was utilized to reduce dimensionality while retaining the most informative features across clinical, proteomic, and combined datasets. Three components were computed, with each retaining 10 latent variables (LVs), which maximized group separation. An orthogonal rotation was applied in the component space to align the axis with the largest group distinction, thereby ensuring that the selected collection of LVs captured the most meaningful variation in the data. Score plots were evaluated and components with the largest degree of separation between 'additional BSI' and 'single BSI' were selected for further analysis.

To validate the robustness of the sPLS-DA model and minimize undue influence by single individuals with our relatively low sample size (n = 30), a feature stability test was performed. Here, one individual was randomly removed from the dataset and models were recorded. This was repeated 10 times. Models were then compared for the most frequently appearing features. Stable features were identified if present in over 80% of models during the 10 iterations. Only stable features were input into the final machine learning models.

Machine learning models were applied to the stable features including non-parametric 685 machine learning models: CatBoost (60), logistic regression (61), and random forest (62). These 686 models were chosen because they do not assume a specific distribution of the data (70), making 687 them ideal for complex clinical and proteomic dataset. Feature selection was performed for each 688 model with subsequent LOOCV, ensuring the most consistent and reliable features were evaluated. 689 This cross-validation approach provided a rigorous evaluation of the model's predictive capability, 690 addressing the challenges posed by our dataset's high dimensionality and limited sample size. 691 Model performance was evaluated by ROC curves, accuracy, sensitivity, and specificity across the 692 models. 693

694 Nonlinear Multivariate Modeling with Genetic Programming

695 Multivariate, linear and nonlinear regression models were generated using Evolved Analytics DataModeler software (Version 9.7) in the SymbolicRegression package. Our modeled 696 outcome was binary as "additional BSI" or "single BSI". Preprocessed data were uploaded as 697 "clinical", "proteomic", or "combined" (clinical + proteomic) datasets. Total models generated 698 699 were 3,020 models for "clinical", 2,435 models for "proteomic", and 3,225 models for "combined", each over 3 rounds of independent modeling at ten iterations each resulting in 30 700 total rounds of modeling. Models were then filtered to the "fittest" models, which represent ~50% 701 of models that satisfied < 80 complexity score and < 0.2 square error rate within the "knee" of the 702 Pareto front. This reduced models to 65 for "clinical, 130 for "proteomic" and 258 for "combined" 703 704 models. Model ensembles were generated and analyzed using the VariablePresence and CreateModelEnsemble functions, which represented the diversity of the filtered models for both 705 complexity and square error rate. Model ensemble statistics are presented in the paper for the 10-706 707 model ensemble for "clinical", 10-model ensemble for "proteomic", and 11-model ensemble for "combined". 708

709 Differential Expression Analysis and Gene Set Enrichment Analysis

ExpressAnalyst package (22) based on the *limma* package (23) in R (R 4.4.1) was utilized 710 for the differential expression analysis (DEA). Data was log₂ transformed and mean-centered. 711 Cutoff criteria included a fold change (FC) > 0.5. A Benjamini-Hochberg false discovery rate 712 (FDR) adjusted p-value < 0.05 was applied. Full data can be found in Data File S5. Time was used 713 714 as a blocking factor for the differential expression analysis. Gene Set Enrichment Analysis (GSEA) was used to map the statistical likelihood that sets of identified proteins relate to biological 715 pathways based on the assumption that the measured proteins would map to gene databases of 716 717 known interaction networks. This approach was used because protein interaction networks are less well developed for high-resolution proteomics and is common for this data type (71). An FDR \leq 718 0.05 and p < 0.05 was also used for the GSEA. A heatmap of the average protein values, z-scored 719 720 across timepoints, was used to display the proteins corresponding to the top up- and downregulated biological pathways. 721

723 Statistical Analysis

Data are reported as mean \pm SEM for time-course analysis of individual proteins. Statistical analysis was performed for time-dependent variation using a linear mixed effect model, *lme4* package (72), in R (R 4.4.1) for time series analysis of select proteins with a Tukey's post-hoc analysis for contrast results of "additional BSI" v. "single BSI", specifically for key proteins in the sPLS-DA and genetic programming models. Statistical significance was determined at p < 0.05and FDR ≤ 0.05 for all components of the study. sPLS-DA and Model ensemble information are presented in the respective sections above.

731

732 List of Supplementary Materials

- 733 Figures S1-S5
- 734 Tables S1-S3
- 735 Data Files S1-S9

736 **References and Notes**

- 1. L. Wentz, P.-Y. Liu, E. Haymes, J. Z. Ilich, Females Have a Greater Incidence of Stress Fractures Than Males in
 Both Military and Athletic Populations: A Systemic Review. *Military Medicine* 176, 420–430 (2011).
- 2. A. S. Tenforde, L. C. Sayres, M. L. McCurdy, K. L. Sainani, M. Fredericson, Identifying sex-specific risk factors
 for stress fractures in adolescent runners. *Medicine & Science in Sports & Exercise* 45, 1843–1851 (2013).
- 3. B. R. Waterman, B. Gun, J. O. Bader, J. D. Orr, P. J. Belmont Jr., Epidemiology of Lower Extremity Stress
 Fractures in the United States Military. *Military Medicine* 181, 1308–1313 (2016).
- 4. J. R. Kardouni, C. J. McKinnon, K. M. Taylor, J. M. Hughes, Timing of Stress Fractures in Soldiers During the
 First 6 Career Months: A Retrospective Cohort Study. *J Athl Train* 56, 1278–1284 (2021).
- 5. M. L. Crunkhorn, L. A. Toohey, P. Charlton, M. Drew, K. Watson, N. Etxebarria, Injury incidence and prevalence in elite short-course triathletes: a 4-year prospective study. *Br J Sports Med* **58**, 470–476 (2024).
- 6. K. L. Bennell, S. A. Malcolm, S. A. Thomas, S. J. Reid, P. D. Brukner, P. R. Ebeling, J. D. Wark, Risk Factors
 for Stress Fractures in Track and Field Athletes: A Twelve-Month Prospective Study. *Am J Sports Med* 24, 810–818
 (1996).
- 750 7. J. Sharma, J. P. Greeves, M. Byers, A. N. Bennett, I. R. Spears, Musculoskeletal injuries in British Army recruits:
 a prospective study of diagnosis-specific incidence and rehabilitation times. *BMC Musculoskelet Disord* 16, 106
 (2015).
- 8. J. P. Greeves, B. Beck, B. C. Nindl, T. J. O'Leary, Current risks factors and emerging biomarkers for bone stress
 injuries in military personnel. *Journal of Science and Medicine in Sport* 26, S14–S21 (2023).
- 9. A. Nattiv, G. Kennedy, M. T. Barrack, A. Abdelkerim, M. A. Goolsby, J. C. Arends, L. L. Seeger, Correlation of
- MRI grading of bone stress injuries with clinical risk factors and return to play: a 5-year prospective study in
 collegiate track and field athletes. *Am J Sports Med* **41**, 1930–1941 (2013).
- 10. T. Hoenig, K. E. Ackerman, B. R. Beck, M. L. Bouxsein, D. B. Burr, K. Hollander, K. L. Popp, T. Rolvien, A.
 S. Tenforde, S. J. Warden, Bone stress injuries. *Nat Rev Dis Primers* 8, 1–20 (2022).
- 11. K. L. Popp, K. E. Ackerman, S. E. Rudolph, F. Johannesdottir, M. A. Hughes, C. Xu, G. Unnikrishnan, J.
- 761 Reifman, M. L. Bouxsein, Changes in Volumetric Bone Mineral Density Over 12 Months After a Tibial Bone Stress
- Injury Diagnosis: Implications for Return to Sports and Military Duty. *The American Journal of Sports Medicine* 49,
 226–235 (2021).
- 12. K. H. Rizzone, K. E. Ackerman, K. G. Roos, T. P. Dompier, Z. Y. Kerr, The Epidemiology of Stress Fractures in
 Collegiate Student-Athletes, 2004–2005 Through 2013–2014 Academic Years. *Journal of Athletic Training* 52,
 966–975 (2017).
- 13. M. Fredericson, A. G. Bergman, K. L. Hoffman, M. S. Dillingham, Tibial stress reaction in runners. Correlation
 of clinical symptoms and scintigraphy with a new magnetic resonance imaging grading system. *Am J Sports Med* 23,
 472–481 (1995).
- 14. A. Cheng, C. E. Vantucci, L. Krishnan, M. A. Ruehle, T. Kotanchek, L. B. Wood, K. Roy, R. E. Guldberg, Early
 systemic immune biomarkers predict bone regeneration after trauma. *Proc Natl Acad Sci USA* 118, e2017889118
 (2021).
- 15. L. Gold, D. Ayers, J. Bertino, C. Bock, A. Bock, E. Brody, J. Carter, V. Cunningham, A. Dalby, B. Eaton, T.
- Fitzwater, D. Flather, A. Forbes, T. Foreman, C. Fowler, B. Gawande, M. Goss, M. Gunn, S. Gupta, D. Halladay, J.
- Heil, J. Heilig, B. Hicke, G. Husar, N. Janjic, T. Jarvis, S. Jennings, E. Katilius, T. Keeney, N. Kim, T. Kaske, T.
- Koch, S. Kraemer, L. Kroiss, N. Le, D. Levine, W. Lindsey, B. Lollo, W. Mayfield, M. Mehan, R. Mehler, M.

- 777 Nelson, S. Nelson, D. Nieuwlandt, M. Nikrad, U. Ochsner, R. Ostroff, M. Otis, T. Parker, S. Pietrasiewicz, D.
- 778 Resnicow, J. Rohloff, G. Sanders, S. Sattin, D. Schneider, B. Singer, M. Stanton, A. Sterkel, A. Stewart, S.
- 779 Stratford, J. Vaught, M. Vrkljan, J. Walker, M. Watrobka, S. Waugh, A. Weiss, S. Wilcox, A. Wolfson, S. Wolk, C.
- 780 Zhang, D. Zichi, Aptamer-based multiplexed proteomic technology for biomarker discovery. *Nat Prec*, 1–1 (2010).
- 16. B. B. Sun, J. C. Maranville, J. E. Peters, D. Stacey, J. R. Staley, J. Blackshaw, S. Burgess, T. Jiang, E. Paige, P.
- 782 Surendran, C. Oliver-Williams, M. A. Kamat, B. P. Prins, S. K. Wilcox, E. S. Zimmerman, A. Chi, N. Bansal, S. L.
- 783 Spain, A. M. Wood, N. W. Morrell, J. R. Bradley, N. Janjic, D. J. Roberts, W. H. Ouwehand, J. A. Todd, N.
- Soranzo, K. Suhre, D. S. Paul, C. S. Fox, R. M. Plenge, J. Danesh, H. Runz, A. S. Butterworth, Genomic atlas of the
 human plasma proteome. *Nature* 558, 73–79 (2018).
- $105 \qquad \text{fullman processes}, 15-75 (2010).$
- 17. J. C. Rohloff, A. D. Gelinas, T. C. Jarvis, U. A. Ochsner, D. J. Schneider, L. Gold, N. Janjic, Nucleic Acid
- Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as Diagnostic and Therapeutic Agents.
 Molecular Therapy Nucleic Acids 3 (2014), doi:10.1038/mtna.2014.49.
- 18. V. Berisha, C. Krantsevich, P. R. Hahn, S. Hahn, G. Dasarathy, P. Turaga, J. Liss, Digital medicine and the curse of dimensionality. *npj Digit. Med.* 4, 1–8 (2021).
- 19. R. Raghuraj K., S. Lakshminarayanan, K. Tun, in 2007 IEEE Congress on Evolutionary Computation, (2007),
 pp. 4154–4161.
- 20. M. Kotanchek, T. Kotanchek, K. Kotanchek, in *Genetic Programming Theory and Practice XIX*, L. Trujillo, S.
 M. Winkler, S. Silva, W. Banzhaf, Eds. (Springer Nature, Singapore, 2023), pp. 91–116.
- 21. J. Wang, D. Duncan, Z. Shi, B. Zhang, WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013.
 Nucleic Acids Research 41, W77–W83 (2013).
- 797 22. P. Liu, J. Ewald, Z. Pang, E. Legrand, Y. S. Jeon, J. Sangiovanni, O. Hacariz, G. Zhou, J. A. Head, N. Basu, J.
 798 Xia, ExpressAnalyst: A unified platform for RNA-sequencing analysis in non-model species. *Nat Commun* 14, 2995
- 799 (2023).
 - 23. M. E. Ritchie, B. Phipson, D. Wu, Y. Hu, C. W. Law, W. Shi, G. K. Smyth, limma powers differential
 expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res* 43, e47 (2015).
- 24. J. Douxfils, C. Klipping, I. Duijkers, V. Kinet, M. Mawet, C. Maillard, M. Jost, J. Rosing, J.-M. Foidart,
- Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters.
 Contraception 102, 396–402 (2020).
- 25. C. V. Coombs, T. J. O'Leary, J. C. Y. Tang, W. D. Fraser, J. P. Greeves, Hormonal contraceptive use, bone
 density and biochemical markers of bone metabolism in British Army recruits. *BMJ Mil Health* 169, 9–16 (2023).
- 26. K. C. Ravindra, V. S. Vaidya, Z. Wang, J. D. Federspiel, R. Virgen-Slane, R. A. Everley, J. I. Grove, C.
- 808 Stephens, M. F. Ocana, M. Robles-Díaz, M. Isabel Lucena, R. J. Andrade, E. Atallah, A. L. Gerbes, S. Weber, H.
- 809 Cortez-Pinto, A. J. Fowell, H. Hussaini, E. S. Bjornsson, J. Patel, G. Stirnimann, S. Verma, A. M. Elsharkawy, W. J.
- H. Griffiths, C. Hyde, J. W. Dear, G. P. Aithal, S. K. Ramaiah, Tandem mass tag-based quantitative proteomic
 profiling identifies candidate serum biomarkers of drug-induced liver injury in humans. *Nat Commun* 14, 1215
- 812 (2023).
- 27. L. N. Bell, R. Vuppalanchi, P. B. Watkins, H. L. Bonkovsky, J. Serrano, R. J. Fontana, M. Wang, J. Rochon, N.
- Chalasani, Serum proteomic profiling in patients with drug-induced liver injury. *Alimentary Pharmacology & Therapeutics* 35, 600–612 (2012).
- 28. J. Jing, Z. Du, Z. Wen, B. Jiang, B. He, Dynamic changes of urinary proteins in a rat model of acute
- 817 hypercoagulable state induced by tranexamic acid. J Cell Physiol 234, 10809–10818 (2019).

- 29. J. Jing, Z. Du, S. Ji, K. Han, Urinary proteome analysis of acute hypercoagulable state in rat model induced by ε aminocaproic acid. *Biomedicine & Pharmacotherapy* 110, 275–284 (2019).
- 30. V. J. Navarro, I. Khan, E. Björnsson, L. B. Seeff, J. Serrano, J. H. Hoofnagle, Liver injury from herbal and dietary supplements. *Hepatology* **65**, 363–373 (2017).
- 31. M. Barrack, M. Fredericson, F. Dizon, A. Tenforde, B. Kim, E. Kraus, A. Kussman, S. Singh, A. Nattiv, Dietary
- 823 Supplement Use According to Sex and Triad Risk Factors in Collegiate Endurance Runners. *The Journal of Strength*
- 824 & Conditioning Research **35**, 404 (2021).
- 32. J. J. Knapik, R. A. Steelman, S. S. Hoedebecke, K. G. Austin, E. K. Farina, H. R. Lieberman, Prevalence of
 Dietary Supplement Use by Athletes: Systematic Review and Meta-Analysis. *Sports Med* 46, 103–123 (2016).
- 33. J. Sundgot-Borgen, B. Berglund, M. K. Torstveit, Nutritional supplements in Norwegian elite athletes—impact
 of international ranking and advisors. *Scandinavian Journal of Medicine & Science in Sports* 13, 138–144 (2003).
- 34. G. K. Dresser, J. D. Spence, D. G. Bailey, Pharmacokinetic-Pharmacodynamic Consequences and Clinical
 Relevance of Cytochrome P450 3A4 Inhibition. *Clin Pharmacokinet* 38, 41–57 (2000).
- 35. M. J. Way, M. A. Ali, A. McQuillin, M. Y. Morgan, Genetic variants in ALDH1B1 and alcohol dependence risk
 in a British and Irish population: A bioinformatic and genetic study. *PLoS One* 12, e0177009 (2017).
- 36. O. Itkonen, E. Koivunen, M. Hurme, H. Alfthan, T. Schröder, U.-H. Stenman, Time-resolved
- immunofluorometric assays for trypsinogen-1 and 2 in serum reveal preferential elevation of trypsinogen-2 in
 pancreatitis. *The Journal of Laboratory and Clinical Medicine* 115, 712–718 (1990).
- 37. W. Wang, L. Wu, X. Wu, K. Li, T. Li, B. Xu, W. Liu, Combined analysis of serum SAP and PRSS2 for the
 differential diagnosis of CD and UC. *Clinica Chimica Acta* 514, 8–14 (2021).
- 38. G. H. Eldjarn, E. Ferkingstad, S. H. Lund, H. Helgason, O. T. Magnusson, K. Gunnarsdottir, T. A. Olafsdottir,
- B. V. Halldorsson, P. I. Olason, F. Zink, S. A. Gudjonsson, G. Sveinbjornsson, M. I. Magnusson, A. Helgason, A.
- Oddsson, G. H. Halldorsson, M. K. Magnusson, S. Saevarsdottir, T. Eiriksdottir, G. Masson, H. Stefansson, I.
- Jonsdottir, H. Holm, T. Rafnar, P. Melsted, J. Saemundsdottir, G. L. Norddahl, G. Thorleifsson, M. O. Ulfarsson, D.
- F. Gudbjartsson, U. Thorsteinsdottir, P. Sulem, K. Stefansson, Large-scale plasma proteomics comparisons through
 genetics and disease associations. *Nature* 622, 348–358 (2023).
- 39. L. Sui, S. Wang, D. Ganguly, T. P. El Rayes, C. Askeland, A. Børretzen, D. Sim, O. J. Halvorsen, G. Knutsvik,
- J. Arnes, S. Aziz, S. Haukaas, W. D. Foulkes, D. R. Bielenberg, A. Ziemys, V. Mittal, R. A. Brekken, L. A. Akslen,
- R. S. Watnick, PRSS2 remodels the tumor microenvironment via repression of Tsp1 to stimulate tumor growth and
- 847 progression. *Nat Commun* **13**, 7959 (2022).
- 40. V. Barresi, V. D. Bella, L. L. Nigro, A. P. Privitera, P. Bonaccorso, C. Scuderi, D. F. Condorelli, Temporary
- serine protease inhibition and the role of SPINK2 in human bone marrow. *iScience* **26** (2023),
- doi:10.1016/j.isci.2023.106949.
- 41. M. Arai, O. Yokosuka, T. Kanda, K. Fukai, F. Imazeki, M. Muramatsu, N. Seki, M. Miyazaki, T. Ochiai, H.
- Hirasawa, H. Saisho, Serum osteopontin levels in patients with acute liver dysfunction. *Scandinavian Journal of Gastroenterology* 41, 102–110 (2006).
- 42. R. Vaschetto, S. Nicola, C. Olivieri, E. Boggio, F. Piccolella, R. Mesturini, F. Damnotti, D. Colombo, P.
- 855 Navalesi, F. Della Corte, U. Dianzani, A. Chiocchetti, Serum levels of osteopontin are increased in SIRS and sepsis.
- 856 Intensive Care Med **34**, 2176–2184 (2008).

- 43. C. Roderburg, F. Benz, D. V. Cardenas, M. Lutz, H.-J. Hippe, T. Luedde, C. Trautwein, N. Frey, A. Koch, F.
- Tacke, M. Luedde, Persistently elevated osteopontin serum levels predict mortality in critically ill patients. *Crit Care* **19**, 271 (2015).
- 44. J. Cassuto, A. Folestad, J. Göthlin, H. Malchau, J. Kärrholm, The key role of proinflammatory cytokines, matrix
 proteins, RANKL/OPG and Wnt/β-catenin in bone healing of hip arthroplasty patients. *Bone* **107**, 66–77 (2018).
- 45. S. Kuppachi, W. Cheungpasitporn, R. Li, Y. Caliskan, M. A. Schnitzler, M. McAdams-DeMarco, J. B. Ahn, S.
- Bae, G. P. Hess, D. L. Segev, K. L. Lentine, D. A. Axelrod, Kidney Transplantation, Immunosuppression and the
- Risk of Fracture: Clinical and Economic Implications. *Kidney Medicine* **4**, 100474 (2022).
- 46. L. T. Mackinnon, Chronic exercise training effects on immune function. *Med Sci Sports Exerc* 32, S369-376
 (2000).
- 47. E. Balfoussia, K. Skenderi, M. Tsironi, A. K. Anagnostopoulos, N. Parthimos, K. Vougas, I. Papassotiriou, G.
- Th. Tsangaris, G. P. Chrousos, A proteomic study of plasma protein changes under extreme physical stress. *Journal*of *Proteomics* 98, 1–14 (2014).
- 48. A. R. Evans, P. V. Giannoudis, P. Leucht, T. O. McKinley, G. E. Gaski, K. P. Frey, J. C. Wenke, C. Lee, The local and systemic effects of immune function on fracture healing. *OTA Int* **7**, e328 (2024).
- 49. W. Schobersberger, B. Wirleitner, B. Puschendorf, A. Koller, B. Villiger, W. Frey, J. Mair, Influence of an ultramarathon race at moderate altitude on coagulation and fibrinolysis. *Fibrinolysis* **10**, 37–42 (1996).
- 50. J. J. N. Posma, J. J. Posthuma, H. M. H. Spronk, Coagulation and non-coagulation effects of thrombin. *Journal*of *Thrombosis and Haemostasis* 14, 1908–1916 (2016).
- 51. D. Prisco, R. Paniccia, V. Guarnaccia, G. Olivo, T. Taddei, M. Boddi, G. F. Gensini, Thrombin generation after
 physical exercise. *Thromb Res* 69, 159–164 (1993).
- 52. T. Herren, P. Bartsch, A. Haeberli, P. W. Straub, Increased thrombin-antithrombin III complexes after 1 h of physical exercise. *Journal of Applied Physiology* **73**, 2499–2504 (1992).
- 53. K. M. Kim, L.-Y. Lui, J. A. Cauley, K. E. Ensrud, E. S. Orwoll, J. T. Schousboe, S. R. Cummings, Osteoporotic
 Fractures in Men (MrOS) Study Research Group, Red Cell Distribution Width Is a Risk Factor for Hip Fracture in
 Elderly Men Without Anemia. *J Bone Miner Res* 35, 869–874 (2020).
- 54. Z. Qi, L. Zhang, Z. Li, H. Yu, Q. Li, L. Ma, Y. Yang, Red cell distribution width: a potential marker of reduced
 femoral neck bone mineral density in men and postmenopausal women. *Endocrine* (2024), doi:10.1007/s12020-02404093-8.
- 55. M. Föcker, N. Timmesfeld, S. Scherag, K. Bühren, M. Langkamp, A. Dempfle, E. M. Sheridan, M. de Zwaan,
 C. Fleischhaker, W. Herzog, K. Egberts, S. Zipfel, B. Herpertz-Dahlmann, J. Hebebrand, Screening for anorexia
- nervosa via measurement of serum leptin levels. J Neural Transm 118, 571–578 (2011).
- 56. J. Hebebrand, W. F. Blum, N. Barth, H. Coners, P. Englaro, A. Juul, A. Ziegler, A. Warnke, W. Rascher, H.
 Remschmidt, Leptin levels in patients with anorexia nervosa are reduced in the acute stage and elevated upon short-
- term weight restoration. *Mol Psychiatry* **2**, 330–334 (1997).
- 57. W. Köpp, W. F. Blum, S. von Prittwitz, A. Ziegler, H. Lübbert, G. Emons, W. Herzog, S. Herpertz, H. C. Deter,
 H. Remschmidt, J. Hebebrand, Low leptin levels predict amenorrhea in underweight and eating disordered females.
- 894 *Mol Psychiatry* **2**, 335–340 (1997).
- 58. M. Mountjoy, K. E. Ackerman, D. M. Bailey, L. M. Burke, N. Constantini, A. C. Hackney, I. A. Heikura, A.
 Melin, A. M. Pensgaard, T. Stellingwerff, J. K. Sundgot-Borgen, M. K. Torstveit, A. U. Jacobsen, E. Verhagen, R.

- Budgett, L. Engebretsen, U. Erdener, 2023 International Olympic Committee's (IOC) consensus statement on
 Relative Energy Deficiency in Sport (REDs). *Br J Sports Med* 57, 1073–1097 (2023).
- 59. M. T. Barrack, J. C. Gibbs, M. J. De Souza, N. I. Williams, J. F. Nichols, M. J. Rauh, A. Nattiv, Higher
- Incidence of Bone Stress Injuries With Increasing Female Athlete Triad–Related Risk Factors: A Prospective
 Multisite Study of Exercising Girls and Women. *Am J Sports Med* 42, 949–958 (2014).
- 60. L. Prokhorenkova, G. Gusev, A. Vorobev, A. V. Dorogush, A. Gulin, in *Advances in Neural Information Processing Systems*, (Curran Associates, Inc., 2018), vol. 31.
- 61. T. G. Nick, K. M. Campbell, *Logistic Regression* (Humana Press, 2007; DOI https://doi.org/10.1007/978-1 59745-530-5_14).
- 62. Y. Qi, in *Ensemble Machine Learning: Methods and Applications*, C. Zhang, Y. Ma, Eds. (Springer, New York, NY, 2012), pp. 307–323.
- 63. S. A. Williams, M. Kivimaki, C. Langenberg, A. D. Hingorani, J. P. Casas, C. Bouchard, C. Jonasson, M. A.
- 909 Sarzynski, M. J. Shipley, L. Alexander, J. Ash, T. Bauer, J. Chadwick, G. Datta, R. K. DeLisle, Y. Hagar, M.
- Hinterberg, R. Ostroff, S. Weiss, P. Ganz, N. J. Wareham, Plasma protein patterns as comprehensive indicators of
 health. *Nat Med* 25, 1851–1857 (2019).
- 912 64. Z. Wang, L. Bian, C. Mo, H. Shen, L. J. Zhao, K.-J. Su, M. Kukula, J. T. Lee, D. W. Armstrong, R. Recker, J.
- 913 Lappe, L. F. Bonewald, H.-W. Deng, M. Brotto, Quantification of aminobutyric acids and their clinical applications
- as biomarkers for osteoporosis. *Commun Biol* **3**, 1–14 (2020).
- 915 65. A. Moen, A.-L. Lind, M. Thulin, M. Kamali-Moghaddam, C. Røe, J. Gjerstad, T. Gordh, Inflammatory Serum
- Protein Profiling of Patients with Lumbar Radicular Pain One Year after Disc Herniation. *International Journal of Inflammation* 2016, e3874964 (2016).
- 918 66. A. Gurinovich, Z. Song, W. Zhang, A. Federico, S. Monti, S. L. Andersen, L. L. Jennings, D. J. Glass, N.
- Barzilai, S. Millman, T. T. Perls, P. Sebastiani, Effect of longevity genetic variants on the molecular aging rate.
 Geroscience 43, 1237–1251 (2021).
- 67. L. Gold, J. J. Walker, S. K. Wilcox, S. Williams, Advances in human proteomics at high scale with the SOMAscan proteomics platform. *New Biotechnology* **29**, 543–549 (2012).
- 68. J. Ambroise, B. Bearzatto, A. Robert, B. Govaerts, B. Macq, J.-L. Gala, Impact of the spotted microarray preprocessing method on fold-change compression and variance stability. *BMC Bioinformatics* **12**, 413 (2011).
- 69. Z. Pang, L. Xu, C. Viau, Y. Lu, R. Salavati, N. Basu, J. Xia, MetaboAnalystR 4.0: a unified LC-MS workflow
 for global metabolomics. *Nature Communications* 15, 3675 (2024).
- 927 70. S. Siegel, Nonparametric Statistics. *The American Statistician* **125**, 497 (1957).
- 928 71. P. Sivakumar, M. Saul, D. Robinson, L. E. King, N. B. Amin, SomaLogic proteomics reveals new biomarkers
 929 and provides mechanistic, clinical insights into Acetyl coA Carboxylase (ACC) inhibition in Non-alcoholic
- 930 Steatohepatitis (NASH). *Sci Rep* **14**, 17072 (2024).
- 72. H. Doran, D. Bates, P. Bliese, M. Dowling, Estimating the Multilevel Rasch Model: With the lme4 Package. *Journal of Statistical Software* 20, 1–18 (2007).
- 933
- 934

Acknowledgments: We would like to acknowledge the clinical research team at Boston

- Children's Hospital for efforts in patient recruitment, data collection, and management.
 We would also like to thank Dr. Mark Kotanchek for assistance with the DataModeler
 software, Dr. Dan Lowd for assistance with machine learning models, Dr. Clay Small and
 Dr. Karl Romanowicz for bioinformatic discussions, as well as Dr. Bill Cresko for
 reviewing the biostatistics, machine learning, and manuscript prior to submission. The
 opinions or assertions contained herein are the private views of the author(s) and are not
 to be construed as official or as reflecting the views of the Army, the Department of
- 943 Defense, National Institute of Health, or the U.S. Government.
- The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or reflecting the views of the U.S. Army or the Department of Defense. Any citations of commercial organizations and trade names in this report do not constitute an official U.S. Army, Department of Defense endorsement of approval of the products or services of these organizations. This paper has been approved for public release with unlimited distribution.
- Artificial intelligence (AI) assisted technologies (ChatGPT-4, GitHub Copilot leveraging ChatGPT40) were used to aid in code revision and debugging as well as revision of text used in the manuscript. All code was evaluated and checked to ensure accuracy and is available on GitHub. Throughout the manuscript, text was reviewed after prompts such as "revise" and "condense" were used to aid in clarification of the text and reducing word count. The authors take full responsibility for both the coding and written content of this manuscript.

957 Funding:

- 958 United States Department of Defense, Defense Health Program, and Joint Program
- 959 Committee (W811XWH-15-C-0024) (PI: Bouxsein ML); Wu Tagi Human Performance Alliance (Multi Play Aslarman KE, Cu
- 960 Wu Tsai Human Performance Alliance (Multi-PIs: Ackerman KE, Guldberg RE);
- 961 NIH-NIDCR, K99DE033689 (PI: Romanowicz GE);
- 962 Knight Campus Undergraduate Scholarship (Dinh)

963 Author contributions:

- 964 Conceptualization: GER, KP, ED, IH, KL, KEA, MLB, REG
- 965 Methodology: GER, KP, ED, IH, KL, REG
- 966 Investigation: GER, KP, ED, IH, JMH, KEA
- 967 Visualization: GER, ED, IH
- Funding acquisition: GER, MLB, KEA, REG
- 969 Project administration: GER, KP, MLB, REG
- 970 Supervision: GER, KP, MLB, REG
- 971 Writing original draft: GER, ED
- 972 Writing review & editing: GER, KP, ED, IH, KL, JMH, KEA, MLB, REG
- 973 **Competing interests:** Authors declare that they have no competing interests.

974 **Data and materials availability:**

- All data are available in the main text or the supplementary materials. Code relating to the analysis is available on GitHub: https://github.com/GuldbergLab/BSLStudy_2024
- 976 the analysis is available on GitHub: <u>https://github.com/GuldbergLab/BSI-Study-2024</u>

977